SCHEMBL2117226

SCHEMBL2117226

COc1cc(S(=O)(=O)N(C)c2cc(-c3ccco3)ccc2C)ccn1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.39
LRRK2 Q5S007 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
KMT2A Q03164 1/20 0.36
PIK3C3 Q8NEB9 1/20 0.35
UBE2I P63279 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
POLB P06746 2/20 0.35
KDM4E B2RXH2 1/20 0.35
S1PR1 P21453 2/20 0.34
LMNA P02545 2/20 0.34
FLT3 P36888 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
TRIM24 O15164 1/20 0.34
ACSS2 Q9NR19 1/20 0.34
PAX8 Q06710 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120046 0.87 CYP2C9 (0.37) CYP2C9CYP11B1CYP11B2KMT2AUBE2I
SCHEMBL2117541 0.87 ACSS2 (0.40) CYP2C9POLBKDM4ELMNATRIM24
SCHEMBL2117311 0.78 HSD17B1 (0.43) CYP2C9KMT2AUBE2ISAE1UBA2
SCHEMBL2117866 0.78 TAAR1 (0.47) CYP2C9KMT2AUBE2ISAE1UBA2
SCHEMBL2118249 0.78 PSEN1 (0.45) CYP2C9KMT2AKDM4ELMNAMAPT
SCHEMBL2119290 0.78 TRIM24 (0.55) CYP2C9POLBKDM4ELMNAMAPT
SCHEMBL15921445 0.72 KDM4E (0.43) LRRK2KMT2APOLBKDM4ES1PR1
SCHEMBL2119068 0.69 PIK3C3 (0.36) CYP2C9CYP11B1CYP11B2KMT2APIK3C3
SCHEMBL2120206 0.68 GAA (0.42) CYP2C9KMT2ALMNATP53MAPT
SCHEMBL2116901 0.67 TRIM24 (0.49) CYP2C9POLBMAPTTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 CYP2C9 2049/4885LRRK2 3323/4885CYP11B1 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.